For the one million people diagnosed with Parkinson’s disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders. Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology†, introducing aDBS for people living with Parkinson’s. This feature personalizes therapy based on a… 

Diese exklusive, mehrjährige Vereinbarung festigt die Partnerschaft und ermöglicht es beiden Organisationen, ihre komplementären Stärken zu nutzen, um Patienten die benötigten Medikamente zu verschaffen, indem sie die wachsende regionale Nachfrage nach Unterstützungsdiensten für klinische Studien für Pharma-, Biotechnologie- und klinische Forschungsorganisationen decken. ACL Specialised Trials ist eines der führenden Labore für klinische Versuche in Australien, das große klinische Versuche in der Biotechnologie und Pharmazie von Phase 1 bis Phase 4 durchführt. Mit einem ausgedehnten Netzwerk von Laboren in ganz Australien verfügt ACL Specialised Trials über umfassende Erfahrung in der Bereitstellung von End-to-End-Pathologielösungen und einer breiten Palette von Zentrallabordienstleistungen für klinische Studien für nationale, standortübergreifende und standortbezogene klinische Studien.

U.S. outpatient prescriptions for hydroxychloroquine and ivermectin increased 2- to 10-fold above pre-pandemic rates, respectively, to treat COVID-19, despite strong evidence disproving their effectiveness, new UCLA-led research shows. Nearly three million COVID-related prescriptions were issued in the three and a half years between January 30, 2020 and June 30, 2023, totaling $272 million in estimated spending. Usage was three times higher among adults aged 65 and older compared with those aged 18 to 64. Ivermectin use in particular was higher among people living in the most socially vulnerable neighborhoods and markedly higher in the Southern United States. These findings, published in the peer-reviewed journal Health Affairs, may inform future policies aimed at reducing the harms caused by reliance on non-evidence-based treatments, especially among vulnerable communities. “Our findings underscore the urgent need for policy reforms to combat misinformation and mistrust in scientific institutions. Eliminating… 

Following an injury, such as a traumatic crush injury, the peripheral nervous system is itself often able to effectively regenerate. This capacity of regeneration is mainly attributable to the Schwann cells of the peripheral nervous system. These cells are real quick-change artists that can transform themselves into repair cells when needed. Unfortunately, the regeneration of nerve cells can be inefficient in some cases. A team of researchers at Johannes Gutenberg University Mainz (JGU) has recently discovered a mechanism that slows down the peripheral nervous system recovery process. „Responsible for this is a protein called histone deacetylase 8, or HDCA8 in short,“ explained neurobiologist Professor Claire Jacob of JGU. „This protein is expressed in Schwann cells. If we remove HDCA8, regeneration occurs more rapidly.“ Interestingly, HDAC8 is specifically produced in Schwann cells surrounding sensory neurons that transmit information on sensations, such…